Skip to main content

Table 4 Patients without ECMO compared to those with ECMO

From: Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study

 

Non-ECMO

ECMO

p

Age [years]

69 (63; 71)

61.5 (56; 65)

 < 0.05

Body Mass Index [kg/m2]

27.8 (25.1; 31.1)

31 (26.2; 37.5)

0.226

SOFA Score [points]

11 (10;14)

11 (10; 13)

0.910

Charlson Comorbidity Index

4 (3; 7)

2 (2; 3)

 < 0.05

Dosis of UFH [mg/h]

1400 (800; 1800)

1600 (1200; 1900)

0.238

LMWH [mg/24 h]

120 (100; 180)

-

-

Horovitz Quotient at ICU admission * [mmHG]

146 (114; 219)

160 (137; 189)

0.487

Lowest Horovitz Quotient during ICU stay * [mmHG]

52 (45; 67.5)

53 (37.5; 67.5)

0.848

Prophylactic Anticoagulation

9 (27%)

3 (14%)

0.195

Intermediate Anticoagulation

11 (33%)

15 (68%)

 < 0.05

Any coagulation-associated Complication

19 (58%)

12 (55%)

0.824

BARC_2

2 (6%)

2 (9%)

0.528

BARC_3c

1 (3%)

1 (5%)

0.999

VTE/ATE at VET

14 (42%)

8 (36%)

0.653

ATE

2 (6%)

0

0.356

DVT

8 (24%)

7 (32%)

0.376

CAT

0

2 (9%)

0.156

PE

11 (33%)

6 (27%)

0.634

In-hospital Death

20 (61%)

10 (45%)

0.269

  1. ECMO Extracorporeal Membrane-Oxygenation, SOFA Sepsis-related organ failure assessment, UFH Unfractionated heparin, LMWH Low-molecular-weight heparin, ICU Intensive Care Unit, BARC Bleeding Academic Research Consortium, VTE Venous Thromboembolism, ATE Arterial Thromboembolism, VET Viscoelastic Testing, DVT Deep Vein Thrombosis, CAT Catheter-Associated Thrombosis, PE Pulmonary Embolismm, ARDS Acute Respiratory Distress Syndrome